Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.

Medicine - 1 Oct 2017

Gao Yayue, Gong Ming, Zhang Chunxia, Kong Xudong, Ma Yigai

Abstract excerpt

RATIONALE: Thrombocytopenia in chronic myelomonocytic leukemia (CMML) is usually attributed to impaired marrow production resulting from cytotoxic drug use or CMML itself ("CMML-induced thrombocytopenia"). In very rare cases, immune thrombocytopenia (ITP) can be a complication of CMML ("CMML-associated ITP"). However, treatment of severe thrombocytopenia in patients with CMML is still a challenge. PATIENT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoates
Share to Decitabine
Share to Hydrazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Chronic

Share to Platelet Count

Share to Purpura, Thrombocytopenic, Idiopathic

Share to Serine-Arginine Splicing Factors

Share to Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 29069007
DOI: 10.1097/MD.0000000000008337
PMCID: PMC5671840

Genes

SRSF2
TET2
TPO
ZRSR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.PMID 29069007Read ↗

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico ApproachSemantic proximity Read ↗

Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.Semantic proximity Read ↗

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.Semantic proximity Read ↗

Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center ExperienceSemantic proximity Read ↗

Immune thrombocytopenia: A review of upfront treatment strategies.Semantic proximity Read ↗

Management of Refractory Immune Thrombocytopenia with Fostamatinib: A Case ReportSemantic proximity Read ↗

A single-center historical control study of eltrombopag combined with immunosuppressive therapy for severe aplastic anemia in childrenSemantic proximity Read ↗

Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune ThrombocytopeniaSemantic proximity Read ↗

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisSemantic proximity Read ↗

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemSemantic proximity Read ↗

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.Semantic proximity Read ↗

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.